nci toxicity grading scale for brentuximab
Epub 2013 Nov 15. Only 2 of the 31 patients who had NT per CTCAE, but grade 0 NT by mCRES and ASTCT, had received corticosteroids (Table 4). is also being studied in the treatment of other conditions and types of phenytoin decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hbbd``b`"\35`= Avoid or Use Alternate Drug. Use Caution/Monitor. . . Stiripentol is a CYP3A4 inhibitor and inducer. The most current release files are in order of appearance: CTCAE_5.0; CTCAE v5.0 in the NCI Thesaurus .xlsx format; CTCAE v5.0 in the NCI Thesaurus .xls format; CTCAE v5.0 in the original CTEP .xlsx format Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. B. C. D. Experts are tested by Chegg as specialists in their subject area. . Thirty minutes later, however, Ms. R developed tingling and numbness in her feet and tongue. endobj th{U j06,`A & NW`c-D&2,s;H$2DD;IXDjzRirTz6>XjNHWa][+RpVR=} \ShV*IQ_O|YAiBXvlX5y,seqHi|@h(cg="b&XY"im|%{7s\fI5I5FMi^Zqickfk,;n+{!iv |z$85w~#e Adjust dose according to prescribing information if needed. . and formulary information changes. $L5'ZZ-.GUK)3~ Modify Therapy/Monitor Closely. fexinidazole will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. z $3-^DpR-!Fi&\Arb,kYRZglm`. Eligible patients were at least 18 years old, with 2 or more prior lines of therapy (including rituximab and an anthracycline), and were ineligible for or had relapsed after autologous hematopoietic stem cell transplantation. This patient information sheet applies only to approved uses of the drug. Seattle, WA: Business Wire; July 7, 2016, Preliminary results of prophylactic tocilizumab after axicabtagene ciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL), Chimeric antigen receptor T-cell therapy - assessment and management of toxicities, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, United Kingdom National Cancer Research Institute, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Avoid coadministration with sensitive CYP3A substrates. Medscape Education, 20022007081-overviewDiseases & Conditions, 20022006680-overviewDiseases & Conditions, encoded search term (brentuximab vedotin (Adcetris)) and brentuximab vedotin (Adcetris), Pfizer in Talks to Buy Cancer Drugmaker Seagen, Brentuximab in Pediatric Hodgkin Lymphoma: 'Paradigm Shift' and Just Approved. If a less serious reaction occurs, the infusion will be interrupted, you will be treated for the reaction, and the infusion will be continued. <> Use Caution/Monitor. 2016;2016:2359437. doi: 10.1155/2016/2359437. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule. 8 0 obj Avoid or Use Alternate Drug. Monitor Closely (1)tucatinib will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Monitor patients for adverse reactions. contributed to the study design; S.J.S. 22-25 June 2017. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. hiM!JE%Y}>0G2dh&b5"?f` 1M\'`('PD,)*+Z{-784qZS5'fh [o=]^'W1 2L_:o0aHIX :#HoZl&]{j%jO palifermin increases toxicity of brentuximab vedotin by Other (see comment). The brentuximab vedotin infusion was again held, and 100 mg of IV methylprednisolone was administered. . This potential conflict of interest has been reviewed and managed by Oregon Health & Science University. Monitor Closely (1)dexamethasone decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. This page contains brief information about brentuximab vedotin efavirenz will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. 0000003200 00000 n Monitor Closely (1)phenytoin decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. R.T.M. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. CTC Version 2.0 Publish Date: April 30, 1999 Cancer Therapy Evaluation Program 1 Revised March 23, 1998 Common Toxicity Criteria, Version 2.0 DCTD, NCI, NIH, DHHS March 1998 posaconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Acute infusion reaction management and subsequent premedication strategies are outlined. Monitor Closely (1)efavirenz will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . MedlinePlus Information on Brentuximab Vedotin - A lay language summary of important information about this drug that may include the following: Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. Use Caution/Monitor. Monitor Closely (2)elagolix will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. These criteria are used for the management of chemotherapy . Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. Four medical experts with experience treating patients with 3 different CD19-targeted CAR-T cell constructs retrospectively assessed and regraded NT after tisagenlecleucel treatment in patients with r/r DLBCL or r/r transformed follicular lymphoma in the JULIET trial, as reported in the US Food and Drug Administration (FDA) prescribing label. Lancet Oncol. Get medical help right away if you develop any signs of PML, including changes in mood, unusual behavior, confusion, difficulty concentrating, changes in vision/speech/walking, decreased strength or weakness on one side of the body. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Monitor Closely (1)efgartigimod alfa will decrease the level or effect of brentuximab vedotin by receptor binding competition. affecting hepatic/intestinal enzyme CYP3A4 metabolism. siponimod and brentuximab vedotin both increase immunosuppressive effects; risk of infection. endobj Monitor patients for adverse reactions. Monitor Closely (1)ceritinib will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. However, much of the information may also apply to unapproved uses that are being studied. An official website of the United States government. All discrepancies were resolved during the adjudication conference that followed group meetings and discussions. Use Caution/Monitor. Specifically, the CTCAE scale leaves much room for subjectivity and does not discern the clinically relevant findings that define immune effector cell-mediated events from nonspecific ones. endstream endobj startxref . Any adverse event occurred was recorded and classified for type and grade using NCI-CTCAE criteria (v 4.0). Bookshelf Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. Specific conditions and symptoms may have values or descriptive comment for each level, but the general guideline is: 1 - Mild 2 - Moderate 3 - Severe 4 - Life-threatening 5 - Death Grade 1: is defined as mild, asymptomatic symptoms. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. 0000000016 00000 n Monitor patients for adverse reactions. nicardipine increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dose of drugs that are CYP3A4 substrates as necessary. Use Caution/Monitor. Both the CRES/mCRES and ASTCT scales appear to suit clinicians needs, with small nuances separating them; however, ICANS scoring per ASTCT is now being adopted by most physicians and regulatory bodies, and we expect it to become the universal grading scale for CAR-T cell therapy-associated NT. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC. belzutifan will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. doi: 10.1200/JCO.2011.38.0410. 2014;12:465471. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: bleomycin, other drugs that weaken the immune system/increase the risk of infection (such as natalizumab, rituximab). stiripentol, brentuximab vedotin. . Monitor Closely (1)cobicistat will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. NCI CTCAE v5.0 hematologic toxicity Neutropenia, thrombocytopenia, anemia, and lymphocytopenia are determined from the complete blood count. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. <>>>/Rotate 180/MediaBox[0 0 612 792]>> Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. Monitor Closely (1)mifepristone will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. A New First-line Regimen for Advanced Hodgkin Lymphoma? government site. Monitor Closely (1)cenobamate will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. This effect was not observed with istradefylline 20 mg/day. Evaluate for loss of therapeutic effect if medication must be coadministered. Use Caution/Monitor. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Monitor patients for adverse reactions. This booklet was validated by means of user evaluation, and then the Delphi consensus method. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. One hundred six patients who received tisagenlecleucel (as of September 2017) were reported in the FDA label. Use Caution/Monitor. 0 Use Caution/Monitor. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. <>stream If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs. rifabutin decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Unauthorized use of these marks is strictly prohibited. voxelotor will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. The .gov means its official. National Library of Medicine If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies. Use Caution/Monitor. Use Caution/Monitor. Monitor patients for adverse reactions. brentuximab vedotin and bleomycin both increase Other (see comment). Monitor patients for adverse reactions. Use Caution/Monitor. Use Caution/Monitor. 0000001820 00000 n nK Comment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Monitor patients for adverse reactions. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. If you log out, you will be required to enter your username and password the next time you visit. Presented at 15th International Conference on Malignant Lymphoma; 18-22 June 2019; Lugano, Switzerland. abametapir will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Information last revised March 2023. Monitor patients for adverse reactions. Use Caution/Monitor. dexamethasone decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Blood Adv 2020; 4 (7): 14401447. enzalutamide will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Canada residents can call a provincial poison control center. NCI Common Terminology Criteria for Adverse Events (CTCAE) data files and related documents are published here. Monitor patients for adverse reactions. informational and educational purposes only. Monitor Closely (1)saquinavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . Avoid or Use Alternate Drug. 2015;385(9980):18531862. Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, Pillon M, Aladjidi N, Klingebiel T, Landman-Parker J, Medina-Sanson A, August K, Sachs J, Hoffman K, Kinley J, Song S, Song G, Zhang S, Suri A, Gore L. Lancet Haematol. Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, and so on. Avoid or Use Alternate Drug. Use Caution/Monitor. To lower your risk, your doctor may add a medication and tell you to drink plenty of fluids. Contribution: R.T.M., S.J.S., D.G.M., and F.L.L. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. Avoid or Use Alternate Drug. Serious - Use Alternative (1)erdafitinib will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Brentuximab Vedotin Hypersensitivity Premedication Protocol, MeSH what this drug is used for and how it is used. is a scientific advisor to Kite/Gilead, Novartis, Celgene/BMS, GammaDelta Therapeutics, and Wugen; and an allogene consultant with grant options for Cellular Biomedicine Group, Inc. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. Given the clear benefits of brentuximab consolidation in improving progression-free survival post transplant (Moskowitz et al., 2015) in high-risk Hodgkin lymphoma, it was thought the benefit of brentuximab vedotin consolidation outweighed the possible risks of subsequent infusions. Tell your doctor right away if you have symptoms of high blood sugar, such as increased thirst/urination. ofatumumab SC, brentuximab vedotin. FDA label information for this drug is available at DailyMed. Contraindicated because of increased risk of pulmonary toxicity. Monitor Closely (1)clarithromycin increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. According to the NCI's. toxicity grading scale, this reaction is a grade: Question: A patient receiving an initial brentuximab infusion experiences severe respiratory distress requiring inthubation. }? commonly, these are generic drugs. Epub 2015 Mar 19. erdafitinib will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Find Clinical Trials for Brentuximab Vedotin - Check for trials from NCI's list of cancer clinical trials now accepting patients. D.G.M. NT by ASTCT criteria provided concordance for 34 patients, a lower grade for 31 patients, and a higher grade for 3 patients compared with the CTCAE scale (Figure 1B). Use Caution/Monitor. Modify Therapy/Monitor Closely. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. If not feasible, avoid use of abametapir. Monitor Closely (1)rifabutin decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . Monitor patients for adverse reactions. . Avoid or Use Alternate Drug. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. Serious - Use Alternative (1)lasmiditan increases levels of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. According to the NCI's. Use Caution/Monitor. Use Caution/Monitor. Minor (1)anastrozole will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . NT regrading of the JULIET trial by CTCAE, modified CRES, and ASTCT criteria highlighted the need for standardized NT grading practices. The same limitation applies to the ICE score, which is a modified version of the CARTOX-10 score and is used in the ASTCT ICANS consensus criteria. ublituximab and brentuximab vedotin both increase immunosuppressive effects; risk of infection. Individual plans may vary restrictions. HHS Vulnerability Disclosure, Help Compare formulary status to other drugs in the same class. Use Caution/Monitor. Monitor Closely (1)atazanavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)tipranavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Accessibility E.S.R. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine. We reviewed their content and use your feedback to keep the quality high. . Monitor Closely (1)fosphenytoin decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. 0000006704 00000 n Monitor patients for adverse reactions. commonly, these are "non-preferred" brand drugs. All material on this website is protected by copyright, Copyright 1994-2023 by WebMD LLC. fosphenytoin decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Q4|o<9RIG"q\b1JEK["O|{Qt2{GgW5HRN~qk+#G$+ Iyao"s7]pUBj" Minor/Significance Unknown. tazemetostat will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. official website and that any information you provide is encrypted Monitor Closely (1)itraconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Key definitions of each NT grade for the 3 assessment tools are outlined in Table 1. lFsA what you should know about this drug before using it, other drugs that may interact with this drug, and. Use Caution/Monitor. The ASTCT grading scale for ICANS is similarly domain-based and uses a modified version of the CARTOX-10 screening tool, called the Immune Effector Cell-Associated Encephalopathy (ICE) score. Use Caution/Monitor. . 2005;66(1):p. 195. doi: 10.1016/j.urology.2005.01.038. St John's Wort decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. <>stream Presented at 24th Congress of the European Hematology Association; 13-16 June 2019; Amsterdam, The Netherlands. nelfinavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Upon reviewing the available literature regarding brentuximab vedotin hypersensitivity reactions, which will be outlined in the discussion summary, we instituted the premedication strategy for subsequent infusions outlined in the Table on p 628. Monitor patients for adverse reactions. Only NT with at least temporal association with CAR-T cell therapy was considered for regrading. commonly, these are "non-preferred" brand drugs or specialty 3 0 obj 1186 0 obj <> endobj j4UY=h2nlYzDG@.Sr {aI}khvU2%3fs+KFR3f. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. Per protocol, NT events in the JULIET trial were identified and graded using the CTCAE v4.03 criteria. Depressed level of consciousness should be attributable to no other cause (eD180X X gD181X X, no sedating medication). 0000000676 00000 n Monitor patients for adverse reactions. 0000001178 00000 n Salvage chemotherapy was administered with ifosfamide carboplatin, and etoposide (ICE). Monitor Closely (1)encorafenib, brentuximab vedotin. Adjust dosage of CYP3A4 substrates, if clinically indicated. Bethesda, MD 20894, Web Policies Novartis is committed to sharing with qualified external researchers access to patient-level data and supporting clinical documents from eligible studies. Consider increasing CYP3A substrate dose if needed. tecovirimat will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Overall, fewer cases of CAR-T cell therapy-related NT were identified by both the mCRES system and the ASTCT criteria compared with the CTCAE scale. Your doctor should order a pregnancy test before you start this medication. Serious - Use Alternative (1)voxelotor will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider increasing CYP3A substrate dose if needed. Monitor patients for adverse reactions. mifepristone will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . To gain a better understanding of tisagenlecleucels NT safety profile, NT-related data collected in the JULIET trial were assessed retrospectively by a panel of medical experts and regraded using the CTCAE criteria in parallel with the mCRES system and the ASTCT criteria. Monitor Closely (1)tazemetostat will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . Lancet Oncol. doi: 10.1016/S2352-3026(18)30153-4. Cytokine release syndrome and neurotoxicity by baseline tumor burden in adults with relapsed or refractory diffuse large B-cell lymphoma treated with tisagenlecleucel [abstract], Analyses of cytokine release syndrome and neurotoxicity by age and lymphodepleting chemotherapy use in adults with relapsed or refractory diffuse large B-cell lymphoma treated with tisagenlecleucel. also provided consultant services to and received payment from Novartis. Fexinidazole inhibits CYP3A4. brentuximab vedotin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. unspecified interaction mechanism. Arora A, Bhatt VR, Liewer S, Armitage JO, Bociek RG. Use Caution/Monitor. Use Caution/Monitor. If coadministration unavoidable, separate administration by at least 6 hr before or after administration of P-gp substrates with narrow therapeutic index. . prescription products. Use Caution/Monitor. Lynch RC, Cassaday RD, Smith SD, Fromm JR, Cowan AJ, Warren EH, Shadman MS, Shustov A, Till BG, Ujjani CS, Libby EN 3rd, Philip M, Coye H, Martino CN, Bhark SL, Morris K, Rasmussen H, Behnia S, Voutsinas J, Gopal AK. Use Caution/Monitor. istradefylline will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. { @,dBm2L:XKolLvYYAo8B.cCe/N : Monitor patients for adverse reactions. The infusion was discontinued with 40 mg of drug remaining, due to the prolonged infusion time. Modify Therapy/Monitor Closely. <]>> Avoid or Use Alternate Drug. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. c_MGq|,`Y8vyD;L}v~@$\OpW2[[ZnFp4`q`/&MbzDBJ:*Y!0J-Xy>VYp{ iAT=`5"u.'wrZ(`E5Qm='X:i6|2{h=[^?aK$#!;N%CljIb`5J2uX6; Use Caution/Monitor. US residents can call their local poison control center at 1-800-222-1222. Use Caution/Monitor. Before Brentuximab vedotin is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone in adults. Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not being bedridden. indinavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Stiripentol is a CYP3A4 inhibitor and inducer. You are being redirected to Median follow-up from time of infusion was 14 months; 93 patients had at least 3 months of follow-up and made up the efficacy analysis set. cancer. As of December 2017, 111 patients received tisagenlecleucel in JULIET. Use Caution/Monitor. . Abstract 254, Kite announces two-year data for Yescarta, Juno Therapeutics reports clinical hold on the JCAR015 phase II ROCKET trial [press release].